Date published: 2026-9-22

1-800-457-3801

SCBT Portrait Logo
Seach Input

Veli1 CRISPR/Cas9 KO Plasmid (h): sc-406559

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Veli1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Veli1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Veli1 CRISPR/Cas9 KO Plasmid (h)

    sc-406559
    20 µg
    $397.00

    Overview

    LIN7A encodes Veli1, a PDZ domain–containing scaffolding protein that helps organize polarized membrane domains by coupling transmembrane receptors and ion channels to cytoskeletal and trafficking machinery. Veli1 participates in the Crumbs polarity complex and related basolateral targeting processes, influencing epithelial polarity, junctional integrity, and receptor localization. Through interactions with MAGUK proteins and other PDZ ligands, LIN7A contributes to signaling organization at the plasma membrane and synaptic compartments. Altered cell polarity and mislocalized signaling complexes are broadly relevant to mechanisms studied in neurodevelopmental and cancer-associated contexts, making LIN7A a useful target for pathway dissection.

    Veli1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LIN7A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LIN7A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LIN7A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Veli1 protein expression.

    This CRISPR knockout system enables efficient generation of LIN7A-deficient cell models for investigation of Veli1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting LIN7A exon(s) critical for Veli1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple LIN7A genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by Veli1 CRISPR/Cas9 KO Plasmid (h) and Veli1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LIN7A locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by Veli1 HDR Plasmid (h) and Veli1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LIN7A homology arms to support homology-directed repair at defined LIN7A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.